Clinical trials: Probable Alzheimer Disease
Probable Alzheimer Disease, Parkinson Disease
In Vivo Alzheimer Proteomics
In France, an estimated 860 000 patients are affected by Alzheimer Disease (AD) which represents, as in other developed countries, a major public health issue.
- Conditions
- Probable Alzheimer Disease, Parkinson Disease, Neurological Disease Without Cognitive Degradation, Brain Trauma
- Trial name
- PROMARA (NCT02263235)
- Testing
- administration of stable isotope-labelled leucine-, collection of CSF, blood, urine, saliva
- Where
- France
- Volunteers
- 89 people
- Sponsor
- University Hospital, Montpellier
Mild Cognitive Impairment, Probable Alzheimer's Disease
Dietary Treatments for Cognitive Impairment in Older Adults
This trial seeks to establish the feasibility of implementing a ketogenic, modified Atkins diet (MAD) to older adults with mild cognitive impairment (MCI) or early Alzheimer's disease (AD) living in the community.
- Trial name
- NCT02521818
- Testing
- Modified Atkins Diet, NIA Diet for Seniors
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Johns Hopkins University
Agitation,Psychomotor, Disruptive Behavior
A Medical Cannabis Oil for Treatment of Agitation and Disruptive Behaviors in Subjects With Dementia.
This double-blind, placebo-controlled study is designed to assess the effectiveness of, MediCane's medical cannabis oil extracted from MediCane's proprietary strain into GMP-grade olive oil, as an add-on therapy to standard of…
- Conditions
- Agitation,Psychomotor, Disruptive Behavior, Dementia, Alzheimer Disease
- Trial name
- NCT06217146
- Testing
- Medical Cannabis
- Where
- 3 sites in Israel
- Volunteers
- 24 people
- Sponsor
- M. H MediCane Ltd.
Alzheimer Disease
Comparative Study to Test Safety and Efficacy of Neurotrophic and Cholinergic Treatment of Alzheimer's Disease
The study was performed to compare the safety and efficacy of Cerebrolysin (10 mililiters [ml]), Aricept (10 miligrams [mg]), and a combination of both treatments on cognitive performance and global function in patients with…
- Trial name
- Combi (NCT00911807)
- Testing
- Cerebrolysin + donepezil
- Where
- 3 sites in Spain
- Volunteers
- 217 people
- Sponsor
- Ever Neuro Pharma GmbH
Alzheimer Disease, Mild Cognitive Impairment
Identification of Patients With a High Probability of Meeting Eligibility Criteria for an Alzheimer's Disease Clinical Trial (APHELEIA)
Apheleia-001 is a prescreener that aims to identify and characterize participants with reported cognitive impairment using demographic information, clinical history, brief cognitive assessments, and blood-based biomarkers to…
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Memory Loss, Memory Disorders
- Trial name
- NCT05364307
- Testing
- Prescreener database
- Where
- 19 sites in United States, Canada
- Volunteers
- 1,555 people
- Sponsor
- Global Alzheimer's Platform Foundation
Alzheimer's Disease
A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease
The purpose of this study is to assess the efficacy, safety, and tolerability of Exelon® patch in patients with probable AD (MMSE 10-20), in order to support a planned regulatory submission and registration of Exelon transdermal…
- Trial name
- NCT01399125
- Testing
- Rivastigmine Patch, Rivastigmine Capsules
- Where
- 16 sites in China
- Volunteers
- 501 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer's Disease
Trial of Rifaximin in Probable Alzheimer's Disease
This study aims to improve cognition and function in patients with Alzheimer's Disease (AD) by administering the oral antibiotic, Rifaximin.
- Trial name
- NCT03856359
- Testing
- Rifaximin 550 milligrams (MG)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Duke University
Alzheimer's Disease
Clinical Effectiveness of 10 cm^2 Rivastigmine Patch in Patients With Alzheimer's Disease
This study evaluated the safety and efficacy of 10 cm^2 rivastigmine patch in patients with Alzheimer Disease (MMSE 10-26). The primary objective was the percentage of patients who stayed on the target size of 10 cm^2 for at…
- Trial name
- ADEPT (NCT00561392)
- Testing
- Rivastigmine 5 and 10 cm^2 patch
- Where
- Germany
- Volunteers
- 208 people
- Sponsor
- Novartis
Alzheimer's Disease
Efficacy and Safety of Rivastigmine Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease
The purpose of this study was to investigate the 5cm^2 and 10cm^2 doses of rivastigmine transdermal patch in terms of efficacy and safety in patients with probable Alzheimer's Disease (MMSE [Mini Mental State Examination] 10-20).
- Trial name
- NCT00423085
- Testing
- Rivastigmine transdermal patch
- Where
- Japan
- Volunteers
- 859 people
- Sponsor
- Novartis Pharmaceuticals
Mild Cognitive Impairment, Alzheimer's Disease
Comparison of PET Amyloid Imaging in Japanese and Western Subjects
This was a Phase 2, multicenter study to assess the extent and patterns of [18F] flutemetamol uptake in the brains of 3 groups of Japanese subjects: healthy volunteers (HV), amnestic mild cognitive impairment (aMCI), and probable…
- Conditions
- Mild Cognitive Impairment, Alzheimer's Disease, Healthy
- Trial name
- NCT02813070
- Testing
- [18F] Flutemetamol
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- GE Healthcare
Dementia, Alzheimer Disease
A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment
The purpose of this study is to evaluate the efficacy and safety of galantamine treatment in patients with mild cognitive impairment.
- Trial name
- NCT00236574
- Testing
- Galantamine hydrobromide
- Volunteers
- 974 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Alzheimer's Disease, Dementia
Blood Gene Expression Signature in Patients Diagnosed With Probable Alzheimer's Disease Compared to Patients Suffering From Other Types of Dementia
The objective of the study is to define the performance of blood-based signatures for Alzheimer's Disease (AD) in different patients populations including AD, non-AD dementia, and non-demented controls.
- Trial name
- NCT00880347
- Testing
- Blood sampling
- Where
- 21 sites in France
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- Exonhit
Alzheimer's Disease
Safety of Switching From Donepezil to Rivastigmine Patch in Patients With Probable Alzheimer's Disease
This study was designed to evaluate the safety and tolerability of switching from donepezil to an initial dose of 5cm^2 rivastigmine patch formulation in patients with probable Alzheimer's Disease (MMSE 10-24).
- Trial name
- NCT00428389
- Testing
- Rivastigmine 5 cm^2 transdermal patch, Rivastigmine 10 cm^2 transdermal patch
- Where
- 23 sites in United States
- Volunteers
- 262 people
- Sponsor
- Novartis
Alzheimer's Disease
Safety and Tolerability of Rivastigmine With Add-on Memantine in Patients With Probable Alzheimer's Disease
This is a prospective, 26-week, open-label, single-arm multi-center pilot study. Eligible patients will receive open-label treatment with rivastigmine capsules plus memantine tablets as add on therapy.
- Trial name
- NCT00305903
- Testing
- Rivastigmine, memantine
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Novartis
Alzheimer Disease, Parkinson Disease
Evaluation of [18F]MNI-1126 as an Imaging Marker for Synaptic Density Loss
The primary objective of this protocol is to examine [18F]MNI-1126 as a tool to assess synaptic density loss.
- Conditions
- Alzheimer Disease, Parkinson Disease, Healthy Volunteers
- Trial name
- NCT03587649
- Testing
- [18F]MNI-1126
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Invicro
Alzheimer Disease
ADvance II Study: DBS-f in Patients With Mild Alzheimer's Disease
The primary efficacy objective of this study is to test the hypothesis that DBS-f stimulation (ON) will slow cognitive and functional progression of AD, as compared to no stimulation (OFF), by measuring baseline…
- Trial name
- NCT03622905
- Testing
- DBS-f On, DBS Off
- Where
- 21 sites in United States, Canada and 1 more
- Volunteers
- 74 people
- Sponsor
- Functional Neuromodulation Ltd
Probable Alzheimer's Disease
Exploratory Open Label Study for Development of a Method To Detect Dendritic Cells
This is a proof-of-concept study designed to confirm that human phagocytic cells can be labeled with the near-infrared dye indocyanine green (ICG) and the presence of the labeled cells 48 hours later in cerebral cortex can be…
- Trial name
- NCT05482867
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- MindImmune Therapeutics, Inc.
Diagnostic Imaging
Evaluation of the Neuroinflammation Pattern of BAY85-8102 F-18, DPA-714 in Probable Alzheimers Disease Patients Versus Healthy Volunteers and Radiation Dosimetry of F 18, DPA-714 in Healthy Volunteers
PET (positron emission tomography) imaging with BAY85-8102 F-18, DPA-714 for investigation of neuroinflammation pattern in probable Alzheimers patients versus healthy volunteers and radiation dosimetry in healthy volunteer.
- Trial name
- NCT01009359
- Testing
- F-18 DPA-714 (BAY85-8102)
- Where
- 2 sites in Finland, Netherlands
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Bayer
Alzheimer's Disease, Central Nervous System Diseases
Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease
This study is being conducted to determine the safety, tolerability, and pharmacokinetics (PK) of three different doses of an investigational medication, EVP-6124, in individuals with mild to moderate Alzheimer's disease who are…
- Trial name
- NCT00766363
- Testing
- EVP-6124 (0.1 mg/day), EVP-6124 (0.3 mg/day), EVP-6124 (1.0 mg/day)
- Where
- 4 sites in United States
- Volunteers
- 49 people
- Sponsor
- FORUM Pharmaceuticals Inc
Active Aging Individuals Aged 65 and Over, Aging
Italian Validation of the dNA Scale and Its Correlation With Neurocognitive Variables
The goal of this experimental multicentric intervention study is to validate, in Italian, the dynamic Neurocognitive Adaptation (dNA) Scale, which has already been validated in English, among a healthy elderly population (aged 65…
- Conditions
- Active Aging Individuals Aged 65 and Over, Aging, Mild Cognitive Impairment (MCI), Dementia
- Trial name
- NCT07533084
- Where
- 8 sites in Italy
- Volunteers
- 265 people, healthy volunteers welcome
- Sponsor
- Neuromed IRCCS